Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$1.77 USD
-0.05 (-2.75%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Brokerage Reports
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 61 - 80 ( 129 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Q123 Results Softer than Expected, Incrementally More Cautious Commentary on CCHW Transaction
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
1Q23 In-Line, Divestitures Uncertainty Leaves Us Cautious
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry Update: April 2023 Performance and Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Consumer & Generation Preferences - 4/20 Special
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: MSO Benchmarking Scorecard Update - Prioritizing Cash Flows
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry Update: 1Q23 Cannabis Performance, Sales, and Valuation
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Consumer- Weekly ReHash: Another Rough Quarter for Cannabis
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
4Q22 Rationalization Focus on Optimization, Lower to Neutral & $1.75 PT
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Q422 Underwhelms on Margins/EBITDA and Outlook Soft. Move to Hold Rating
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Tightening Capital Markets Conditions Poses Both Risks and Opportunities for Cannabis Companies
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry: Monthly Performance and Valuations February ''23
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Announces Timeline Extension to Close Cresco/Columbia Acquisition
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: 280E Removal Would Bring More Than Just Financial Leverage
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly Rehash: U.S. Interstate Commerce the Long Game
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S